Webinar: Uncovering CAR-T and CAR-NK Cell Potency Using Multi‑analyte Profiling

Demonstrating effector cell potency remains a critical requirement for CAR-T and CAR-NK cell therapy development, yet reliance on single-analyte readouts such as IFN-γ can limit functional insight.

This webinar presents a data-driven approach that integrates multiplex screening with sensitive quantification to enable deeper characterization of immune cell potency.

Presenting data based on CD19-CAR-T and CD19-CAR-NK cells from multiple donors, the session will show how targeted multi-analyte assays support more representative potency assessment, aligned with evolving regulatory expectations.

Key takeaways 

• Review comparative secretion profiling data identifying 29 differentially secreted analytes in CD19-CAR-T cells and 13 in CD19-CAR-NK cells from an initial 123-analyte screen
• Learn how multi-analyte protein biomarkers provide a more representative measure of effector cell potency than IFN-γ alone
• See data from a streamlined approach that moves from broad discovery and effector cell characterization to tailored, multi-analyte potency assays for immunotherapies
• Understand how this approach enables more comprehensive characterization of immune cell function to better define potency and therapeutic relevance